Anaptysbio ANAB
NASDAQ ANAB
$56.40 -1.06 (-1.84%)
As of: Sep 4, 2026 · 12:48 PM EDT

Anaptysbio (ANAB) Non Operating Interest Expenses (2016 - 2019)

Analysis

Anaptysbio (ANAB) Non Operating Interest Expenses (2016 - 2019) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 93.62 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn 20.27 Mn
10 Anaptysbio 1.62 Bn 1.33 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2019 200,000.00
Sep 30, 2019 240,000.00
Jun 30, 2019 281,000.00
Mar 31, 2019 320,000.00
Dec 31, 2018 365,000.00
Sep 30, 2018 400,000.00
Jun 30, 2018 436,000.00
Mar 31, 2018 451,000.00
Dec 31, 2017 456,000.00
Sep 30, 2017 452,000.00
Jun 30, 2017 439,000.00
Mar 31, 2017 428,000.00
Dec 31, 2016 111,000.00
Sep 30, 2016 116,000.00
Jun 30, 2016 116,000.00
Mar 31, 2016 115,000.00